Closing in on human immunodeficiency virus-1

Nature Medicine

Volumn 2, Issue 3, 1996, Pages 274-275

  Mellors, John W ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SHORT SURVEY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0029968740     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0396-274     Document Type: Short Survey

References (23)

1. Aboulker, J.P. & Swart, A.M. Preliminary analysis of the Concorde trial. Lancet 329, 889-890 (1993).
2. Fischl, M.A. et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann. Intern. Med. 122, 24-32 (1995).
3. Delfraissy, J.F. et al. Abstracts of the IXth Int. Conference on AIDS, Berlin, Germany, p. 69 (1993).
4. Danner, S.A. et al. Abstracts of the IXth Int. Conference on AIDS, Berlin, Germany, p. 69 (1993).
5. Chow, Y.K. et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361, 650-654 (1993).
6. Emini, E.A. et al. HIV and multidrug resistance. Nature 364, 679 (1993).
7. Larder, B.A., Kellam, P. & Kemp, S.D. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365, 451-453 (1993).
8. Mellors, J.W. Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, p. 175 (1996).
9. Hammer, S.M., Katzenstein, D.A., Hughes, M.D., Hirsch, M.S. & Merigan, T.C. Abstracts 3rd Conf. Retroviruses and Opportunistic Infections, Washington, DC, p. 175 (1996).
10. Cameron, B. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p. 162 (1996).
11. Freimuth, W.W. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p. 162 (1996).
12. Gulick, R. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p. 162 (1996).
13. Mathez, D. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p. 106 (1996).
14. Coffin, J.M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489 (1995).
15. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
16. Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
17. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p. 174 (1996).
18. Mellors, J. et al. Abstracts 35th Intersci. Conf. on Antimicrobial Agents and Chemotherapy, San Francisco, California, p. 235 (1995).
19. Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571 (1995).
20. Steigbigel, R.T. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p. 80 (1996).
21. Danner, S.A. et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333, 1528-1533 (1995).
22. Markowitz, M. et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333, 1534-1539 (1995).
23. Schapiro, J.M., Winters, M.A., Kozal M.J. & Merigan, T.C. Abstracts 35th Intersci. Conf. Antimicrobial Agents and Chemotherapy, San Francisco, California, p. S8 (1995).